Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Chrono-log Corp.
| Company | Chrono-log Corp. |
|---|---|
| Instrument name | Whole Blood Optical Lumi-Aggregation System 700-2, 700-4 |
| Contact | Sal Pema |
| City State | Havertown, PA |
| Phone | 610-853-1130 or 800-247-6665 |
| Website | |
| First year sold | 2006 |
| List price/Model type | —/benchtop |
| Dimensions (H × W × D)/Weight/Instrument footprint | per each 2-channel module: 8.5 × 14 × 18 in./40 lbs./1.75 sq. ft. |
| No. of units in clinical use in U.S./Outside U.S. | — |
| Composition of installs: Hospital lab/Reference lab/Other | — |
| Targeted daily, monthly, annual test volume | — |
| Operational type | discrete |
| Country where analyzer designed/Manufactured | U.S./U.S. |
| Company manufactures instrument | yes (also sold via distribution partners) |
| FDA-approved clotting-based tests | — |
| FDA-approved chromogenic tests | — |
| FDA-approved immunologic tests | platelet agglutination with ristocetin |
| Other FDA-approved tests | whole blood impedance platelet aggregation, LTA platelet aggregation, platelet dense granule ATP release, ristocetin cofactor assay |
| User-defined tests in clinical use | whole blood impedance platelet aggregation, LTA platelet aggregation, platelet dense granule secretion, ristocetin cofactor assay |
| Tests in development or awaiting FDA 510(k) clearance | — |
| Methodologies supported | turbidimetric for measuring platelet aggregation in PRP and ristocetin cofactor assay, impedance for measuring platelet aggregation in whole blood |
| Number of different measured assays onboard simultaneously | 2–4 |
| Number of different assays programmed and calib. at one time | 2–4 |
| No. of user-definable (open) channels/No. active simultaneously | 2–4/2–4 |
| Factor assays require manual manipulation or dilutions | yes (manual dilutions) |
| Test throughput per hour/Assay run time | 6 (12–24 tests in throughput)/6 min. minimum |
| Design of sample-handling system | manual |
| Operates on whole blood or spun plasma | whole blood and spun plasma |
| Reagent type | self-contained multiuse vials; open reagent system (liquid, lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | no |
| No. of reagent containers held onboard/Reagents ready to use | —/requires operator prehandling |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | no/no/no |
| Reagents, consumables loaded without interrupting testing | yes (consumables) |
| Instrument uses proprietary or third-party reagents | proprietary reagents |
| Maximum time same lot number of reagents can be used | 18 months–3 years |
| Walkaway capability/Walkaway duration | yes/6 min. or 2–4 specimens or 2–4 tests |
| Min.–max. specimen volume that can be aspirated at one time | 225–500 µL |
| Min. sample volume required for PT/PTT/Factor VIII activity | — |
| Types of disposables used | cuvettes, stir bars, disposable electrodes, pipette tips |
| Primary tube sampling supported/Pierces caps on primary tubes | no/no |
| Accommodates most standard tube sizes/Nonstandard sizes | no/no |
| Sample barcode-reading capability/Autodiscrimination | no/no |
| Auto tracks product volume/Measures number of tests remaining | no/no |
| Short sample detection | no |
| Clot detection as preanalytical variable in plasma sample | no |
| Auto detects adequate reagents for aspiration or analysis | no |
| Detection or quantitation for hemolysis, turbidity, icterus, lipemia | no |
| Dilutes patient samples onboard | no |
| Automatic rerun capability/Auto reflex testing capability | yes/no |
| Lag time during which hypercoagulable sample not detected | no |
| User can adjust reagent volumes/Sample volumes | yes/yes |
| User can adjust No. of reagents/Sources of reagents | yes/yes |
| User can adjust incubation times/Reading times | yes/yes |
| Autocalibration/Calibrants stored onboard | yes/no |
| Multipoint calibration supported/Recommended frequency | yes/annually |
| • PT alone | — |
| • PT, PTT | — |
| • Fibrinogen | — |
| • Factor VIII activity assay | — |
| • D-dimer | — |
| Time delay from ordering stat to aspiration of sample | — |
| How labs get LOINC codes for results | email query |
| Onboard real-time QC/Onboard software capability to review QC | yes/no |
| Information that can be barcode-scanned on instrument | barcode scanning not offered |
| Compatible with laboratory automation systems | no |
| Data-management capability/LIS or EHR systems interfaced | onboard/none |
| Interface supplied by instrument vendor | no |
| Results transferred to LIS as soon as test time complete | no |
| Bidirectional interface capability | no |
| Remote servicing provided/UPS backup power supply | no/no |
| Instrument connections to transfer information | — |
| Interface standards supported | — |
| Information transferred to data-management software | — |
| Avg. time for basic user training | 1.5 days (at customer site) |
| Approximate scheduled maintenance time | preventive maintenance and calibration by clinical engineering recommended annually |
| Maintenance records kept onboard | yes |
| Warranty with purchase/Annual service contract cost (24/7) | yes/— (cost dependent on contract) |
| Distinguishing features (supplied by company) | 3 instruments in 1: whole blood/impedance and PRP/LTA aggregometer plus luminometer to measure platelet ATP release; continuously monitors and regulates temperature and stirring; optical calibration can be performed by laboratory personnel using no-cost water samples |